NEOPLASMS

This early-stage trial is testing a drug called dostarlimab in 730 people with advanced solid tumors that have not responded to other treatments. Dostarlimab works by helping the immune system recognize and attack cancer cells. The study is checking for safe doses and any side ef…

This early-phase trial tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma who have had a stem cell transplant. The treatment uses the patient's own T cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called CD30. The m…

This early-phase trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. The study involves 158 adults with advanced solid tumors (like lung or head and neck cancers) that have no…

This phase 2 trial tests a personalized cell therapy called Lete-Cel in 7 people with advanced synovial sarcoma or myxoid/round cell liposarcoma that has not been treated before. Participants receive their own immune cells that have been engineered to recognize and attack their c…

This early-phase trial tests a new type of immunotherapy for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are genetically modified to recognize and attack can…

This study tests whether bevacizumab, a drug that blocks blood vessel growth, can reduce how often people with recurrent respiratory papillomatosis (RRP) need surgery to clear wart-like growths from their airways. About 21 adults who need at least two surgeries per year will rece…

This phase 2 trial is testing a combination of four drugs—irinotecan, dabrafenib, trametinib, and either cetuximab or panitumumab—as a second-line treatment for people with metastatic colorectal cancer that has a BRAF V600E mutation. The study aims to see how well this drug mix s…

This study aimed to test an experimental virus therapy called G207, combined with a single dose of radiation, in children whose high-grade glioma had come back after prior treatment. The virus was injected directly into the brain tumor to kill cancer cells and trigger an immune r…

This study tests a new drug called E7386 combined with other cancer drugs in people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The goal is to find the safest and most effective dose and to see if the combination can shrink tumors. About 300 …

This study follows 120 patients with various cancers—including leukemia, lymphoma, and solid tumors—who already saw benefit from the drugs JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants continue their treatment while researchers monitor for serious side ef…

This study tests a new treatment for people with CD30-positive Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapies. The treatment involves taking a patient's own T cells, adding a gene that helps them recognize and attack CD30 on cancer cells,…

This program offers taletrectinib, an experimental drug, to adults with advanced or spreading ROS1-positive non-small cell lung cancer who cannot join a current clinical trial or use approved treatments. Participants must have a confirmed ROS1 gene fusion and adequate organ funct…

This early-stage study tests an experimental pill, ATV-1601, in adults with advanced solid tumors or certain breast cancers that have a specific AKT1 gene change. The main goals are to find a safe dose and check how the drug moves through the body. About 134 participants will tak…

This study tests whether adding the drug dostarlimab to standard chemotherapy helps people with advanced or recurrent endometrial cancer live longer without their cancer getting worse. About 785 participants will receive either dostarlimab plus chemo or a placebo plus chemo. The …

This phase 2 trial tests a treatment called Lete-Cel, which uses a patient's own immune cells that have been specially trained to attack cancer cells. It is for people with advanced synovial sarcoma or myxoid/round cell liposarcoma whose tumors have a specific marker (NY-ESO-1) a…

This early-phase study tests a new drug called remzistotug, alone or with other cancer treatments, in 152 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. This is a first-in-human trial, so …

This study looks at how well the drug osimertinib combined with chemotherapy works as the first treatment for people with advanced EGFR-mutant non-small cell lung cancer. It involves 532 adults with stage IIIB, IIIC, or IV disease who cannot have surgery or radiation. Researchers…

This early-stage study tests a new drug called GSK3745417, given alone or with another drug (dostarlimab), in about 97 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. This is a…

This study gives people with myelofibrosis continued access to the drug momelotinib, which helps control the disease. It includes 237 participants who were already taking the drug in earlier studies and have not had their disease get worse. The goal is to check long-term safety a…

This early-stage study tests a new experimental drug called GSK6097608, given alone or with other cancer medicines, in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Abo…

This early-stage study tests a new oral drug (GSK4524101) alone and with another drug (niraparib) in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 42 partic…

This study tests whether a combination of two targeted drugs (encorafenib and cetuximab), given alone or with chemotherapy, works better than standard chemotherapy for people with a specific genetic form of advanced colorectal cancer (BRAF V600E mutation) that has spread and hasn…

This early-phase study tests a new experimental drug, BI 765179, in adults with advanced solid tumors or head and neck cancer. The first part finds the safest dose when given alone or with another drug (ezabenlimab). The second part tests it with pembrolizumab in head and neck ca…

This study tests a new treatment using a patient's own immune cells that are genetically modified to better recognize and attack certain solid tumors. It is for people with advanced cancers like synovial sarcoma that have not responded to other treatments. The goal is to see if t…

This study tests a new drug called TSR-022 in people with advanced solid tumors that have not responded to other treatments. The drug is an antibody that targets a protein on immune cells to help fight cancer. The trial has two parts: first, finding the safest dose, and then test…

This study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…

This study tests a new drug called JNJ-63723283 that helps the immune system fight cancer. It is for people with advanced cancers like lung, melanoma, bladder, and others that have not responded to standard treatments. The goal is to find the best dose and see if it can shrink tu…

This study offers ongoing treatment with alectinib or crizotinib to about 200 adults with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche trial. The main goal is to monitor safety and side effects as patients continue therapy after the…

This early-stage study tests a new treatment called ACIT-1, which uses donated immune cells to help fight cancer. About 34 adults with pancreatic or other cancers will receive one of four doses to find the safest and most effective dose. The goal is to see if the therapy can safe…

This study tests whether contrast-enhanced mammography (CEM) finds breast cancer more accurately than standard mammography in women who have already had breast cancer. About 1,647 women ages 30-85 will get both types of mammograms to compare detection rates and false alarms. The …

This study aims to create a new way to screen for many types of cancer using just a routine blood test. Researchers will analyze data from 10 million people to train a computer model that can spot signs of cancer. The goal is to develop a low-cost, non-invasive tool that could be…

This study tests a 3-month strength training program designed for Hispanic prostate cancer survivors and their caregivers. Participants exercise together in remote group classes to improve physical and mental health. The goal is to see if the program is practical and helpful for …

This study tests a 7-week group program led by trained peers (not doctors) to help cancer survivors recently finished with curative treatment manage anxiety and depression. 234 participants from Denmark join weekly sessions to build skills in self-managing emotional symptoms. The…

This 10-year observational study will follow 500 children with growth hormone deficiency who are receiving the once-weekly injection somapacitan as part of their routine care. Researchers will track side effects, medication errors, and new cases of cancer or type 2 diabetes. The …

This study tests whether a wearable patch called TempTraq, which continuously monitors body temperature, can detect fever earlier than standard checks in cancer patients receiving immunotherapy. Early detection of fever may help prevent cytokine release syndrome (CRS) from becomi…

This study tests a program called Potlako+ that combines community education, support for healthcare providers, and patient navigation to help people with cancer symptoms get diagnosed and treated faster. About 874 participants in Botswana will be split into two groups: one recei…

This study reviews existing medical records to understand how blood clots (VTE) are treated in people with active cancer or a history of cancer. Researchers will look at which blood thinners are used, how often clots come back, and the costs involved. No new treatments are given—…

This study enrolls up to 10,000 cancer patients at the National Cancer Institute who are not in active treatment trials. Participants receive standard medical care while researchers collect health information and samples to build a data repository. The goal is to support future c…

This study is tracking over 1,300 people who are having a lung biopsy or lesion localization with the Ion Endoluminal System, a robotic device. The goal is to see how often the device successfully gets a diagnosis and how often complications like a collapsed lung or bleeding occu…

This study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects, so doctors can better prevent or manage them in future treatments. No new treatments or visits are involved—only existi…

This study looks at whether educating doctors in small and mid-sized city hospitals can improve how they test and treat patients with advanced non-small cell lung cancer. About 1000 patients will be observed to see if more patients get the right molecular tests and targeted treat…

This study tests a modified clinical program to help doctors better prevent blood clots (VTE) in cancer patients starting treatment. About 25 patients and their doctors will take part. The program includes education for doctors and a structured risk assessment to decide if blood-…

This study tests a new technology that adjusts the radiation beam in real time to follow lung tumors as they move with breathing. About 20 adults with early-stage lung cancer or limited lung metastases will receive standard radiotherapy with this tracking system. The main goal is…